Arimidex Bone Mass Index and Oral Bisphosphonates (ARBI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00809484
Recruitment Status : Completed
First Posted : December 17, 2008
Last Update Posted : January 6, 2009
Information provided by:
Hellenic Breast Surgeons Society

Brief Summary:
To investigate the management of bone health in postmenopausal women with early breast cancer (BCA) scheduled to receive anastrozole. Postmenopausal women with hormone receptor-positive early BCA are assigned to 1 of 3 strata depending on their pre-existing risk of fragility fracture. Patients (pts) with a bone mineral density (BMD) T-score <-2.0 for either spine or hip are designated higher-risk (H) for fracture and receive anastrozole 1 mg/day plus risedronate orally. Moderate-risk (M) pts (T-score <-1.0 for spine or hip but -2.0 at both sites) are randomized to receive anastrozole plus risedronate (A+R) or anastrozole alone. Pts with T-scores -1.0 at both spine and hip were designated lower-risk (L) and receive anastrozole alone. All pts receive calcium and vitamin D. Lumbar spine and total hip BMD are assessed at baseline, 12, and 24 months.

Condition or disease
Breast Cancer Bone Density

Study Type : Observational
Actual Enrollment : 220 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.
Study Start Date : May 2004
Primary Completion Date : February 2007
Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bone Density
Drug Information available for: Anastrozole
U.S. FDA Resources

1: Low risk
Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
2:Moderate risk
Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
3:High risk
Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Posmenopusal women with endocrine responsive breast cancer who are treated with the aromatase inhibitor anastrozole

Inclusion Criteria:

  • Postmenopausal women
  • ER and or PgR positive breast cancer
  • Completed Surgery and =/- chemotherapy

Exclusion Criteria:

  • metastases
  • history of fractures
  • HRT or SERMs
  • Liver or kidney disfunction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00809484

Hellenic Breast Surgeons Society
Athens, Greece, 11527
Sponsors and Collaborators
Hellenic Breast Surgeons Society

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Markopoulos Christos, Hellenic Breast Surgeons Society Identifier: NCT00809484     History of Changes
Other Study ID Numbers: D5392L0027
First Posted: December 17, 2008    Key Record Dates
Last Update Posted: January 6, 2009
Last Verified: December 2008

Keywords provided by Hellenic Breast Surgeons Society:
Bone Mineral density
Aromatase Inhibitors

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists